Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Kirk's Market Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Sun Tzu who wrote (9750)	5/13/2020 12:02:29 PM
From: Kirk ©	Read Replies (3) \| Respond to of 26745

So much for all the dorks who believe Dr. Fauci and China hatched this elaborate plot for this virus to kill 100s of thousands so they can sell Remdesivir for $1,000 a dose and get rich... then again.... maybe it is too hard to reverse engineer... Gilead signs licenses for generic companies to make and sell remdesivir in 127 countries By ED SILVERMAN @Pharmalot MAY 12, 2020 Under the agreements, the companies can set their own prices, but will not have to pay royalties to Gilead until the World Health Organization declares an end to the public health emergency for the novel coronavirus, or until another medicine or vaccine is approve to treat or prevent Covid-19. The companies include Cipla, Hetero Labs, Jubilant Lifesciences, Mylan, and Ferozsons. The arrangements are formally called non-exclusive voluntary licenses, which is a similar approach Gilead has taken in the past in response to pressure to widen access to its hepatitis C medicines. In this instance, the deals cover mostly low-income and lower-middle income countries, but also some upper-middle- and high-income countries that Gilead said face significant obstacles to access. The move follows the release of preliminary trial results which indicated remdesivir can successfully treat serious cases of Covid-19. The disclosure prompted the Food and Drug Administration quickly authorized emergency use for hospitals. For the moment, Gilead plans to eventually donate 1.5 million doses, which could cover between 140,000 and 280,000 patients, depending on dosing. .... “Of course, this is all predicated on the assumption that remdesivir is easy to reverse-engineer, as was the case with small-molecule AIDS drugs, so the barriers to production are largely legal. If the drug is as difficult to produce as Gilead says, then it’s not clear what compulsory licenses will accomplish, anyway. We’re still learning a lot about the drug itself.” More at statnews.com